---
title: "Sacituzumab govitecan"
slug: "sacituzumab-govitecan"
date: "2023-11-20"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Antibody Drug Conjugates]]

# Sacituzumab govitecan

- Mechanism:
  - Antitrophoblast cell-surface antigen 2 (Trop-2) antibody coupled to topoisomerase 1 inhibitor SN-38;
  - binds to Trop-2 & is internalized so SN-38 can cause DNA damage, apoptosis, & cell death
- Approved indications:
  - Breast cancer,
  - urothelial cancer
- Dosing:
  - 10 mg/kg d 1 & 8 of 21-d cycle;
  - slow infusion if infusion rxn occurs;
  - reduce dose for neutropenia & neutropenic fever;
  - hold dose for grade 3-4 diarrhea, reduce dose for grade 3-4 nausea/vomiting
- PK/PD:
  - T1/2 15.3 h;
  - free SN-38 T1/2 19.7 h
- AEs:
  - Diarrhea,
  - nausea/vomiting,
  - cytopenia,
  - â†“ Ca,
  - â†“ Na,
  - â†‘ LFTs,
  - fatigue
- DDI: UGT1A1 substrate
